Effect of Medications on Prevention of Secondary Osteoporotic Vertebral Compression Fracture, Non-vertebral Fracture, and Discontinuation Due to Adverse Events: a Meta-analysis of Randomized Controlled Trials

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2019 Sep 2

PMID 31472671

Citations 27

Authors

Yuan-Zhe Jin

Jae Hyup Lee

Bin Xu

Minjoon Cho

Affiliations

Soon will be listed here.

Abstract

Background: Bone loss with aging and menopause increases the risk of fragile vertebral fracture, osteoporotic vertebral compression fracture (OVCF). The fracture causes severe pain, impedes respiratory function, lower the quality of life, and increases the risk of new fractures and deaths. Various medications have been prescribed to prevent a secondary fracture, but few study summarized their effects. Therefore, we investigated their effects on preventing subsequent OVCF via meta-analyses of randomized controlled trials.

Methods: Electronic databases, including MEDLINE, EMBASE, CENTRAL, and Web of Science were searched for published randomized controlled trials from June 2015 to June 2019. The trials that recruited participants with at least one OVCF were included. We assessed the risk of bias of every study, estimated relative risk ratio of secondary OVCF, non-vertebral fracture, gastrointestinal complaints and discontinuation due to adverse events. Finally, we evaluated the quality of evidence.

Results: Forty-one articles were included. Moderate to high quality evidence proved the effectiveness of zoledronate (Relative Risk, RR: 0.34; 95% CI, 0.17-0.69, p = 0.003), alendronate (RR: 0.54; 95% CI: 0.43-0.68; p < 0.0001), risedronate (RR: 0.61; 95% CI: 0.51-0.73; p < 0.0001), etidronate (RR, 0.50; 95% CI, 0.29-0.87, p < 0.01), ibandronate (RR: 0.52; 95% CI: 0.38-0.71; p < 0.0001), parathyroid hormone (RR: 0.31; 95% CI: 0.23-0.41; p < 0.0001), denosumab (RR, 0.41; 95% CI, 0.29-0.57; p < 0.0001) and selective estrogen receptor modulators (Raloxifene, RR: 0.58; 95% CI: 0.44-0.76; p < 0.0001; Bazedoxifene, RR: 0.66; 95% CI: 0.53-0.82; p = 0.0002) in preventing secondary fractures. Moderate quality evidence proved romosozumab had better effect than alendronate (Romosozumab vs. alendronate, RR: 0.64; 95% CI: 0.49-0.84; p = 0.001) and high quality evidence proved that teriparatide had better effect than risedronate (risedronate vs. teriparatide, RR: 1.98; 95% CI: 1.44-2.70; p < 0.0001).

Conclusion: Zoledronate, alendronate, risedronate, etidronate, ibandronate, parathyroid hormone, denosumab and selective estrogen receptor modulators had significant secondary prevention effects on OVCF. Moderate quality evidence proved romosozumab had better effect than alendronate. High quality evidence proved PTH had better effect than risedronate, but with higher risk of adverse events.

Citing Articles

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Beaudart C, Veronese N, Douxfils J, Amuthavalli Thiyagarajan J, Bolzetta F, Albanese P Osteoporos Int. 2025; .

PMID: 40047881 DOI: 10.1007/s00198-025-07440-1.

Wang F, Sun R, Zhang S, Wu X J Orthop Surg Res. 2024; 19(1):844.

PMID: 39696524 PMC: 11657487. DOI: 10.1186/s13018-024-05337-z.

Effectiveness of bone-filled mesh bag technology and angle vertebroplasty in the treatment of osteoporotic thoracic vertebral compression fractures in the elderly.

Tang C, Liu F Am J Transl Res. 2024; 16(7):3289-3297.

PMID: 39114704 PMC: 11301485. DOI: 10.62347/GHNQ5649.

Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials.

Kobayashi T, Hara M, Shimanoe C, Morimoto T, Masaaki M, Ito K J Bone Miner Metab. 2024; 42(5):492-502.

PMID: 38977437 DOI: 10.1007/s00774-024-01531-5.

Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.

Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T Osteoporos Int. 2024; 35(8):1377-1393.

PMID: 38733394 DOI: 10.1007/s00198-024-07118-0.

References

Peichl P, Rintelen B, Kumpan W, Broll H . Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol Endocrinol. 1999; 13(1):7-14. DOI: 10.1080/09513599909167526. View

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J . Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000; 85(5):1895-900. DOI: 10.1210/jcem.85.5.6603. View

Guanabens N, Farrerons J, Perez-Edo L, Monegal A, Renau A, Carbonell J . Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone. 2000; 27(1):123-8. DOI: 10.1016/s8756-3282(00)00303-3. View

Moher D, Pham B, Klassen T, Schulz K, Berlin J, Jadad A . What contributions do languages other than English make on the results of meta-analyses?. J Clin Epidemiol. 2000; 53(9):964-72. DOI: 10.1016/s0895-4356(00)00188-8. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Shiota E, Tsuchiya K, Yamaoka K, Kawano O . Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. J Orthop Sci. 2001; 6(2):133-6. DOI: 10.1007/s007760100060. View

10.

Gutteridge D, Stewart G, Prince R, Price R, Retallack R, Dhaliwal S . A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not.... Osteoporos Int. 2002; 13(2):158-70. DOI: 10.1007/s001980200008. View

11.

Brumsen C, Papapoulos S, Lips P, Geelhoed-Duijvestijn P, Hamdy N, Landman J . Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res. 2002; 17(6):1057-64. DOI: 10.1359/jbmr.2002.17.6.1057. View

12.

Cryer B, Bauer D . Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc. 2002; 77(10):1031-43. DOI: 10.4065/77.10.1031. View

13.

Sorensen O, Crawford G, Mulder H, Hosking D, Gennari C, Mellstrom D . Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003; 32(2):120-6. DOI: 10.1016/s8756-3282(02)00946-8. View

14.

Naves M, Diaz-Lopez J, Gomez C, Rodriguez-Rebollar A, Rodriguez-Garcia M, Cannata-Andia J . The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int. 2003; 14(6):520-4. DOI: 10.1007/s00198-003-1405-4. View

15.

Recker R, Stakkestad J, Chesnut 3rd C, Christiansen C, Skag A, Hoiseth A . Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004; 34(5):890-9. DOI: 10.1016/j.bone.2004.01.008. View

16.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

17.

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K . Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004; 22(5):462-8. DOI: 10.1007/s00774-004-0508-0. View

18.

Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T . A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004; 22(5):469-78. DOI: 10.1007/s00774-004-0509-z. View

19.

Lufkin E, Wahner H, OFallon W, Hodgson S, Kotowicz M, Lane A . Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992; 117(1):1-9. DOI: 10.7326/0003-4819-117-1-1. View

20.

Chesnut 3rd C, Majumdar S, Newitt D, Shields A, Van Pelt J, Laschansky E . Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005; 20(9):1548-61. PMC: 4445726. DOI: 10.1359/JBMR.050411. View